Cyclacel Pharma's (CYCC) Phase 3 SEAMLESS Crosses Futility Boundary; DSMB Doesn't See Study Reaching Significant Results
Tweet Send to a Friend
Cyclacel Pharma (NASDAQ: CYCC) announced enrollment of 486 patients, continuation to final analysis and recommendations of the independent Data and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
